TAE-226 is a potent dual inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (InsR), making it a valuable compound in cancer research. It has shown significant antitumor activity in preclinical studies, particularly in cancers driven by IGF signaling pathways such as glioblastoma, neuroblastoma, and certain sarcomas. By blocking these receptors, TAE-226 inhibits downstream signaling cascades that promote tumor cell proliferation, survival, and metastasis. It has also demonstrated the ability to cross the blood-brain barrier, which enhances its potential use in treating brain tumors. Due to its targeted mechanism, TAE-226 is being explored as a therapeutic agent in resistant or aggressive cancers where conventional therapies have limited efficacy.